重大事件
外國發行人報告
6-K
2026-07-28
Lakefront Biotherapeutics 6-K披露回購進展 7月斥資逾240萬歐元回購9.5萬股
AI 繁中摘要
美國 SEC 6-K 申報：Lakefront Biotherapeutics 公佈股份回購進展 📄
比利時梅赫倫，2026 年 7 月 28 日 – Lakefront Biotherapeutics NV（Euronext & NASDAQ: LKFT）今日提交 6-K 表格，披露其於 2026 年 6 月 9 日宣佈的回購計劃最新進展。在 7 月 20 日至 24 日期間，公司透過獨立金融中介的酌情授權，合共回購 95,670 股普通股。
回購細節如下：
- 平均每股作價：€25.41
- 總回購金額：€2,431,442.30
- 最低價：€24.56，最高價：€26.40
- 交易市場涵蓋阿姆斯特丹交易所（XAMS）、CEUX、AQEU 及 TQEX
截至 2026 年 7 月 24 日收市，Lakefront 共持有 606,719 股自身普通股。
公司簡介：Lakefront（前稱 Galapagos）為一家生物科技企業，專注於免疫及炎症領域的高未滿足醫療需求，核心管線包括潛在首創及同類最佳 BCMAxCD3 T 細胞接合器 gamgertamig，用於自體免疫疾病。公司擁有強大資本狀況及交易能力，旨在透過收購及推進高質資產創造長期股東價值。
⚠️ 投資者影響：持續股份回購反映管理層對公司價值的信心，並有望為股價提供支持。然而，回購計劃受市場條件及監管限制，投資者應留意相關風險。前瞻性陳述涉及已知及未知風險，詳情請參閱公司向 SEC 提交的文件（包括 20-F 年報）。
展開英文正文
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
Acquisition of Own Shares
Mechelen, Belgium; July 28, 2026, 22.01 CET; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that between July 20, 2026 and July 24, 2026, it has repurchased 95,670 Lakefront shares via a discretionary
mandate to an independent financial intermediary, as follows:
Date
of purchase
Market/MTF
Number
of shares
Average
price paid (€)
Total
(€)
Lowest
price paid (€)
Highest
price paid (€)
20/07/2026
XAMS
17,936
26.05
467,150.29
25.62
26.40
20/07/2026
CEUX
3,372
25.79
86,979.73
25.70
26.14
20/07/2026
AQEU
101
25.72
2,597.72
25.72
25.72
20/07/2026
TQEX
74
26.22
1,940.28
26.22
26.22
21/07/2026
XAMS
14,022
25.59
358,820.18
25.34
25.80
21/07/2026
CEUX
1,506
25.57
38,513.84
25.52
25.66
21/07/2026
AQEU
227
25.53
5,795.01
25.52
25.70
21/07/2026
TQEX
506
25.56
12,931.79
25.52
25.58
22/07/2026
XAMS
15,385
25.61
394,028.31
25.48
25.72
22/07/2026
CEUX
1,245
25.63
31,907.36
25.62
25.68
22/07/2026
AQEU
490
25.62
12,553.80
25.62
25.62
22/07/2026
TQEX
185
25.68
4,750.13
25.62
25.68
23/07/2026
XAMS
17,120
25.13
430,292.37
24.70
25.62
23/07/2026
CEUX
2,945
24.81
73,071.34
24.74
25.12
23/07/2026
AQEU
61
24.78
1,511.58
24.78
24.78
23/07/2026
TQEX
61
24.78
1,511.58
24.78
24.78
24/07/2026
XAMS
17,407
24.81
431,940.78
24.56
25.00
24/07/2026
CEUX
1,729
24.77
42,830.62
24.60
24.98
24/07/2026
AQEU
1,159
24.91
28,875.91
24.62
24.96
24/07/2026
TQEX
139
24.75
3,439.68
24.62
24.92
Total
95,670
25.41
2,431,442.30
24.56
26.40
As of market close on July 24, 2026, Lakefront holds 606,719 of its own ordinary shares.
About Lakefront BiotherapeuticsLakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology
company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The
Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class
and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility,
and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver
meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us
on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:Investor Relations Sherri Spear+1
412 522 [email protected]
Forward-looking statementsThis press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often,
but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.